leadf
logo-loader
viewANGLE PLC

ANGLE hails major progress, targets regulator submissions in third quarter of 2020

The biopsy firm said its full De Novo FDA submission is in preparation so that it can be “rapidly submitted” once additional samples are analysed following a delay caused by the coronavirus pandemic

ANGLE PLC - ANGLE hails major progress, targets regulator submissions in third quarter of 2020

ANGLE PLC (LON:AGL) has hailed “major progress” in its latest results as it targeted regulatory submission for its Parsortix system to the US Food and Drug Administration (FDA) in the third quarter of 2020.

Parsortix is designed to capture and harvest circulating tumour cells from metastatic breast cancer patients.

WATCH: ANGLE PLC's Andrew Newland updates as blood donations restart to support its key studies

In an outlook statement accompanying results for the eight months ended December 31, 2019, the liquid biopsy specialist said its full De Novo FDA submission is in preparation so that it can be “rapidly submitted” once the remaining analytical samples needed to meet requirements identified in a meeting in January were available and analysed.

While the samples had been delayed by restrictions during the coronavirus pandemic, which had prevented the recruitment of volunteer blood donors, ANGLE said work was back in progress and the FDA submission was expected in the third quarter of the year.

The company added that it is also making progress with its ovarian cancer test, with patient enrolment expected to complete by the end of 2020 with the aim of supporting a laboratory-developed test for ovarian cancer in the new year.

In its figures for the eight months, following a change in the company’s accounting reference date to December 31 from April 30, ANGLE reported a pre-tax loss of £7.7mln compared to a £10.9mln loss for the year ended April 30, 2019, while revenues were £581,000 compared to £678,000 in the comparative period.

ANGLE also reported it had raised gross proceeds of £18mln during the year from institutional investors, including new “significant” backers in the US, and as such had ended the year with a cash balance of £18.8mln.

“During the period, we raised further growth capital, expanding our existing UK shareholder base and adding key new US investors. ANGLE has a robust balance sheet with sufficient working capital and liquidity. We remain confident about the Group's long-term prospects", said ANGLE’s non-executive chairman Garth Selvey.

Shares in ANGLE were 0.8% lower at 59p in early deals on Thursday.

Quick facts: ANGLE PLC

Price: 43.5 GBX

AIM:AGL
Market: AIM
Market Cap: £93.7 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Angle’s Newland reflects on excellent year as cancer patient trials advance

Angle Plc (LON:AGL, OTCMKTS:ANPCY) is poised to revolutionise cancer treatment with its Parsortix system, here we catch up with chief executive Andrew Newland. As Newland explains Parsortix can capture cancer cells from blood, which is very significant for the emerging field of...

on 07/28/2016

2 min read